Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

Abstract Background Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resistance involve activating receptor point...

Full description

Bibliographic Details
Main Authors: Luis D. Borrero-García, Maria del Mar Maldonado, Julia Medina-Velázquez, Angel L. Troche-Torres, Luis Velazquez, Nilmary Grafals-Ruiz, Suranganie Dharmawardhane
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cancer
Subjects:
Therapy resistance
Breast cancer
Tyrosine kinase inhibitors (TKIs)
Rac inhibitors
EHop-016
MBQ-167
Online Access:https://doi.org/10.1186/s12885-021-08366-7

Internet

https://doi.org/10.1186/s12885-021-08366-7

Similar Items